The answer so far
A medicine acting on several targets may have a useful combined effect, an unwanted interaction, or both. A target list is a hypothesis about mechanism, not proof of patient benefit.
A medicine can affect several targets because it may be deliberately designed to activate related proteins, may bind more than one target as a consequence of its structure, or may reach concentrations that engage additional targets. The number of targets is not, by itself, a measure of benefit.156
On this page
One molecule is shown at three receptor targets: GIP, GLP-1 and glucagon. Each can lead to a downstream response.
Three meanings of several targets
A deliberately multi-target molecule is designed to act on more than one chosen target. These targets can include receptors, enzymes, channels or transporters. This is often called polypharmacology. A disease can involve interacting processes, so coordinated activity may be a useful hypothesis. But a target list is not proof that every interaction contributes to benefit. A review of polypharmacology also distinguishes intended targets from antitargets whose interactions may cause adverse effects.5
Specific is not the same as exclusive
Receptor families can share structural features, so a molecule may bind several members with different affinities and efficacies. “Selective” means preference under specified assay conditions; it does not mean that binding to every other target is impossible. The apparent selectivity can change with concentration, exposure time, tissue distribution and competing molecules. For clinical relevance, investigators also need to ask which fraction is free to leave the bloodstream, whether an active metabolite contributes, and whether the concentration at the target tissue is high enough for the measured interaction; a total plasma concentration alone may not answer those questions. An interaction found outside the intended target is not automatically harmful, but it needs evidence of binding, functional activity, relevant exposure and a plausible link to an outcome.2
Binding is not the same as a clinical effect
Evidence sits at several levels. A binding assay can show association with a protein. A cell assay can show a downstream signal in a particular system. An animal study can test exposure and physiology in a whole organism. A human trial can test prespecified outcomes in a selected population. Each step adds information and introduces new questions about dose, distribution, compensatory biology, adherence and outcomes that matter to people. FDA clinical-pharmacology guidance describes mechanism at receptor or cellular, tissue, physiological-system and whole-body levels; a receptor diagram cannot substitute for evidence at those later levels.67
A concrete example: retatrutide
Retatrutide is described in the 2023 phase 2 obesity trial as an agonist at the GIP, GLP-1 and glucagon receptors. The study therefore provides an example of a molecule developed around three related hormonal targets, rather than an accidental interaction discovered only after marketing. It enrolled 338 adults with obesity, or overweight with a weight-related condition, and compared several retatrutide dose groups with placebo for 48 weeks. At week 48, the 12-mg regimen starting at 2 mg had a model-estimated mean weight change of −24.2% versus −2.1% with placebo under the study’s hypothetical efficacy estimand. The primary endpoint was measured earlier, at 24 weeks; the 48-week figure was secondary and does not predict an individual response.89
What that example does—and does not—show
The trial shows a substantial measured outcome in that selected population. It does not identify how much of the result came from each receptor, prove that all three actions are individually necessary, or establish long-term clinical benefit. The investigators describe possible augmentation from glucagon-receptor activation as a rationale to investigate, not a complete causal decomposition. The trial also reported gastrointestinal effects, changes in heart rate and serious adverse events, and its population and duration limit what can be inferred about later use.8
One molecule is not the same as a combination
Two separate medicines can differ in where they go, how long they remain and how their effects overlap. One multi-target molecule has its own exposure profile and dose-response relationships. Neither arrangement is automatically better; comparisons need evidence for the particular products, populations and outcomes. A multi-target mechanism can also include opposing effects that require careful balance across tissues.42
Do not add up arrows as benefits
Three arrows on a mechanism diagram are not three independent clinical benefits. Pathways can interact, signalling can differ by cell type, and desired effects can come with harms. Two medicines can share one target but differ in potency, tissue exposure, functional activity at other targets, schedule and trial population. A headline result from one molecule cannot be transferred to another just because their target lists overlap.52
A five-question check
Which targets were selected in advance, and which interactions were discovered later? At what concentrations and in which assay systems were they measured? Did the molecule change a cell signal, a physiological measure or a patient-important outcome? What evidence connects each proposed target to benefit, harm or neither? Were the population, comparator, follow-up and adverse-event data sufficient for the claim? The most defensible conclusion may be that the molecule interacts with several targets while the clinical value of the combination remains a separate question.57
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- How Do Medicines Work?NIH / NIGMS · Official scientific explainer
- Clinical pharmacodynamicsIUPHAR Pharmacology Education Project · Professional educational reference
- What to know about retatrutideEli Lilly and Company · Sponsor status statement — not independent efficacy evidence
- What Happens to Medicine in Your Body?NIH / NIGMS · Official scientific explainer
- Polypharmacology: The science of multi-targeting moleculesPubMed-indexed review · Peer-reviewed pharmacology review
- Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological ProductsU.S. Food and Drug Administration · Regulator labeling guidance
- Step 3: Clinical ResearchUS Food and Drug Administration · Regulator explanation
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialJastreboff et al. / New England Journal of Medicine · Peer-reviewed randomised clinical trial; primary report
- Retatrutide: the 2023 Phase 2 obesity trial — PubMed recordNational Library of Medicine · Bibliographic and abstract record; full appraisal not inferred